|
Getting your Trinity Audio player ready...
|
Synergy CHC Corp. (NASDAQ: SNYR) is rapidly emerging as one of the most compelling small-cap opportunities in the booming consumer health sector. With shares trading around $1.96, Roth Capital has issued a Buy rating and a $10 price target, pointing to significant upside backed by strong fundamentals.
In Q1 2025, Synergy posted GAAP EPS of $0.10 on $8.2 million in revenue, marking its ninth consecutive quarter of profitability. Gross margins surged to 75.4%, up from 72.0% YoY, driven by an improved product mix. Looking ahead, analysts forecast $47.1 million in 2025 revenue, with EPS projected to climb as consumer health demand accelerates.
The company’s flagship brands—FOCUSfactor and Flat Tummy—are gaining market share and fueling international expansion, including the launch of a Mexico subsidiary and a new Ready-To-Drink product line. Synergy is also proactively refinancing debt to extend maturity to 2029, strengthening its financial position for long-term growth.
With a scale-ready product suite, global reach, and growing brand momentum, Synergy CHC is well-positioned to capitalize on a thriving market. Roth Capital report.
Synergy CHC Corp. (NASDAQ: SNYR) has been featured alongside industry innovators including Navitas Semiconductor (NASDAQ: NVTS), Vigil Neuroscience (NASDAQ: VIGL), Longevity Health Holdings (NASDAQ: XAGE), MicroAlgo Inc. (NASDAQ: MLGO), Peraso Inc. (NASDAQ: PRSO), NVIDIA (NASDAQ: NVDA), and Health In Tech Inc. (NASDAQ: HIT) see article — spotlighting key players driving momentum across AI, biotech, and consumer health. SNYR also shares coverage with breakout disruptors SharpLink Gaming Inc. (NASDAQ: SBET), E2open Holdings (NYSE: ETWO), and MicroCloud Hologram Inc. (NASDAQ: HOLO) in our multi-sector review of high-potential stocks under $10. See the full article for complete insights.